Active not recruitingPHASE2INTERVENTIONAL

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

Agenus Inc.

Enrolment target

150

Start

12 Dec 2022

Estimated completion

01 Feb 2028

Advanced Melanoma

What is this study about?

This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.

Who may be eligible?

Age 18 Years to any · Sex: ALL

Locations (51)

Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, United States
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton, United States
Providence Saint John's Health Center
Santa Monica, United States
Yale University School of Medicine - Yale Cancer Center
New Haven, United States
Georgetown University Medical Center
Washington D.C., United States
Dana-Farber Cancer Institute
Boston, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, United States
Universitair Ziekenhuis Brussel
Jette, Belgium
Oncosite - Centro de Pesquisa Clinica Em Oncologia
Ijuí, Brazil
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
Jaú, Brazil
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Porto Alegre, Brazil
INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil

+39 more sites — see the official record for the full list.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.